Fellows 2026-2027

Meet New Harrison Fellows

The Dr. Stephen A. Harrison Patient Advocacy Fellowship is pleased to welcome its second cohort of Fellows.

Selected through a competitive process led by an independent Selection Committee, these 20 patient advocates bring diverse experiences, perspectives, and a shared commitment to strengthening the patient voice in liver disease research, drug development, and health policy.

Representing communities across the United States, United Kingdom, Portugal, and Spain, the Fellows bring lived experience spanning the spectrum of steatotic liver disease (SLD), including MASLD, MASH, MetALD, and alcohol-associated liver disease (ALD).

2026–2027 Harrison Fellows

  • Lori Botello — Tucson, Arizona, USA

  • Jim Caldwell — Georgetown, Texas, USA

  • Willis Frank Dungan — Central Mississippi, USA

  • Dianne Gillard — London, United Kingdom

  • D. Scott Graham — Manassas, Virginia, USA

  • Jo Anne Henry — Roanoke, Virginia, USA

  • Kathryn J. Hudson — Baltimore, Maryland, USA

  • Gema Iribar — Zarautz, Spain

  • Karen V. Kwinn — Denver, Colorado, USA

  • Georgeta Lester — Raleigh, North Carolina, USA

  • Wendy Lo — San Francisco, California, USA

  • Lesley Anne Manning — Plymouth, United Kingdom

  • Gary Miller — Stamford, Connecticut, USA

  • Terri Milton — Houston, Texas, USA

  • Tricia Nichols — Murfreesboro, Tennessee, USA

  • Joana Pina — Vila Real, Portugal

  • Jerry Rosenberg — Jacksonville, Florida, USA

  • Jillian Sanchez — McAllen, Texas, USA

  • Claudia S. Tamayo-Torres — Brighton, Massachusetts, USA

  • Ken Wong — San Ramon, California, USA

A Year of Learning, Collaboration, and Advocacy

Throughout the Fellowship year, participants will engage in structured educational sessions, mentorship, professional networking, and applied advocacy activities designed to strengthen their understanding of clinical research and regulatory decision-making.

Building on the foundation established by the inaugural cohort, the 2026–2027 Fellows will continue advancing Dr. Stephen A. Harrison's legacy of ensuring that patients are active partners in shaping the future of liver disease research and treatment.